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OBJECTIVES: There has been recent controversy regarding the effectiveness of
vertebral augmentation (balloon kyphoplasty (BKP) and vertebroplasty (VP)) for
treating vertebral compression fractures (VCFs). Limited cost comparisons of BKP
and VP suggest that initial hospital costs are higher for BKP (Mehio 2011), however
costs for subsequent post-operative care are unknown. The present study sought
to characterize and compare the treatment costs for BKP and VP patients through
2 years post-surgery.METHODS:Using the 2005-2009 5%Medicare claims data, BKP
and VP patients were identified using ICD-9-CM and CPT-4 codes. Treatment costs
(Medicare reimbursement/payment adjusted to June 2011 dollars) were compiled
for all components of treatment during the 2-year follow-up. Length of stay (LOS)
and treatment costs for BKP and VP patients were compared using logistic regres-
sion, adjusting for gender, age, census region, comorbidities (Charlson score), race,
socio-economic status (Medicare buy-in status), cancer diagnosis (presence in prior
12 months) and year of surgery. RESULTS: A final cohort of 2878 BKP and 1,609 VP
patients was included. LOS was 3.5 / 4.1 days and 5.5 / 4.3 days for BKP and
VP patients who had inpatient procedures, corresponding to 43% shorted LOS (ad-
justed) for BKP (p0.001). There were no significant differences in average adjusted
treatment costs for BKP and VP patients within the first 3 (p0.097) and first 6
months (p0.142). For the remaining periods, however, BKP patients had lower
adjusted costs (p0.025). At 2 years, the average adjusted costs were 7% lower for
BKP (p0.005). CONCLUSIONS: Although BKP and VP patients in the Medicare pop-
ulation were found to have similar treatment costs within the first six months
following surgery, BKP was found to be cost saving compared to VP subsequently
over time through 2 years.
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OBJECTIVES: To compare clinical and economic outcomes of patients with bone
fracture nonunion receiving non-invasive electrical bone growth stimulator
(EBGS), low-intensity pulsed ultrasound stimulator (LIPUS), or neither stimulation
(No-stim) treatment. METHODS: Medical and pharmacy claims from a U.S. com-
mercially-insured population were analyzed to select patients aged65 who were
newly diagnosedwith nonunion fracture between July 2006 to September 2009. The
date of receiving the first nonunion diagnosis was set as the index date. Three
cohorts were constructed based on the first treatment patients received within
one-year after the index date: EBGS, LIPUS or No-stim. Baseline demographic and
clinical characteristics, and healthcare costs during 9 months before and 1 year
after the index date were assessed. Multivariate regression analyses were per-
formed to compare health care costs incurred in one-year after the index date
between cohorts. RESULTS: A total of 11,628 patients with nonunion fracture
(mean age 45.4 years; 46% males) were identified (EBGS: 29.5%, LIPUS: 12.3%, No-
stim: 58.2%). More than half of the patients (51.8%) had facture-related treatments
in one-year after the index date, and EBGS patients had lower proportion than
LIPUS (37.0% vs. 45.1% , p0.01) and No-stim cohorts (37.0% vs. 60.7%, p0.01).
Patients receiving EBGS were less likely to have at least one hospitalization during
one-year post-index period (14.8% vs. 19.5%, and 14.8% vs. 23.9%, both p0.01).
EBGS cohort had statistically significant lower health care costs in 1-year after
index date than LIPUS (mean: $20,743 vs. $23,271, p0.01) and No-stim cohorts
(mean: $20,743 vs. $24,315, p0.01). Adjusting for variables such as demographic
and clinical characteristics, EBGS patientsmaintained their statistically significant
lower health care costs in one-year after the index date than LIPUS (predicted costs:
$21,632 vs. $23,964, p0.01) and No-stim cohorts (predicted costs: $21,632 vs.
$23,843, p0.01). CONCLUSIONS: Nonunion fracture patients receiving non-inva-
sive electronic stimulation had lower health care costs than patients receiving
ultrasound stimulation or no stimulation.
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OBJECTIVES: Endometrial ablation has emerged as a minimally invasive alterna-
tive to hysterectomy for pre-menopausal patients suffering from menorrhagia.
Less invasive ablation procedures include thermal balloon endometrial ablation
using GYNECARE THERMACHOICE® III (Ethicon, Inc.), and radio-frequency endo-
metrial ablation using NovaSure® (Hologic, Inc.). This study compares costs of
achieving desired treatment outcomes with Thermachoice versus Novasure abla-
tion techniques.METHODS: A value analysis model was developed to estimate the
cost-per-patient treated with either device – overall, and for achieving desired
treatment outcomes of ‘amenorrhea’, ‘return to normal bleeding’, and ‘patient
satisfaction’. Subsequent hysterectomy was also modeled as a failure outcome.
Costs were included for the ablation device, disposables, operating room (OR) time,
and subsequent hysterectomy. Capital expenditure for controller was included for
Thermachoice, but not for Novasure, to represent a best possible scenario for No-
vasure. Analysis was performed from a hospital buyer perspective, over 1- and 3-
years following initial ablation procedure. Sensitivity analyses were conducted by
forcing reductions in clinical effectiveness and simultaneous increase in subse-
quent hysterectomy for procedure with lesser costs in the base cases. RESULTS:
100 hypothetical patients underwent each procedure. Overall cost-per-patient was
lower for Thermachoice over both 1 and 3 year timeframes – offering a saving of
about 4% compared toNovasure. For specific outcomes, savingswere between 6.9%
for ‘patients achieving amenorrhea’ to 7.8% for ‘patients returning to normal bleed-
ing’ in 1 year and between 3.8% and 4.8% for all outcomes in the 3 year scenario.
Sensitivity analyses showed that Thermachoice continued to offer savings in over-
all cost-per-patient compared to Novasure even with a reduction of all effective-
ness outcomes and increase in subsequent hysterectomy rates by about 50% and
18% in the 1- and 3-year scenarios. CONCLUSIONS: In our model, endometrial
ablation with Thermachoice offered cost savings – compared to Novasure, in
achieving desired short and long term treatment outcomes.
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OBJECTIVES: There is controversy regarding the most appropriate method to ana-
lyze cost data. We examined the role of censoring, model fit and assumption vio-
lations in a study determining the costs of dialysis modality for the treatment of
kidney failure.METHODS: All incident dialysis patients from Alberta from 1999 to
2003 were tracked for direct medical costs (inpatient and outpatient costs, physi-
cian claims, and medication costs) for three years using administrative datasets,
and categorized into peritoneal dialysis (PD) only, hemodialysis (HD) only, or mo-
dality switches (HD to PD; PD to HD). Unadjusted censored and uncensored cumu-
lative costs were determined using the non-parametric method of Lin and boot-
strapping. Model fit and assumption violations for alternate covariate adjusted
regression models were assessed through comparison of various approaches (OLS
or GLM regression, log-transformation, smearing), and the optimal approach
identified. RESULTS: Three year adjusted cumulative costs for patients receiving
PD only and HD to PD groups were $58,724 ($44,123-$73,325; 95% confidence inter-
val) and $114,503 ($96,318-$132,688) respectively, andwere significantly lower than
patients receiving HD only $175,996 ($134,787-$217,205) and PD technique failure
patients $173,308 ($147,725-$119,891). Comparison of censored and uncensored
unadjusted total cumulative costs yielded similar results. Covariate adjusted GLM
regression was the best fit for modeling total cumulative costs when compared to
otherOLS andGLMmodels. For cost categorieswith smaller sample sizes (inpatient
costs; n674), GLM models fitted poorly due to kurtosis, and OLS regression on
log-transformed costs with smearing yielded better less biased estimates.
CONCLUSIONS: GLM regression methods for estimating costs performed well
when applied to our analyseswith larger datasets (n1000), but gave biased results
when smaller datasetswere used.Whenmodeling costswith smaller sample sizes,
the most appropriate regression method can be determined through model diag-
nostics.
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OBJECTIVES: The purpose of this study was to estimate the cost of chest X-ray by
activity based costing approach. METHODS: Study was conducted at radiology
department, Penang General Hospital, Penang, Malaysia. The activities involved in
producing a chest X-ray in the hospital were first identified through interviewwith
key personnel in the radiology department. Human resource costwas calculated by
multiplying the mean time spent (in minutes) by employees doing specific activity
to their per-minute salaries. The costs of consumables and clinical equipments
were obtained from the procurement section of the radiology department. The cost
of the building was calculated by multiplying the area of space used by the chest
X-ray facility with the unit cost of public building department. Moreover, straight-
line deprecation with a discount rate of 3% was assumed for calculation of equiv-
alent annual costs for building and machines. Cost of electricity was calculated by
multiplying number of kilo watts used by electrical appliance (chest X-ray facility)
in the year 2010 with electricity tariff for Malaysian commercial consumers (MYR
0.31 per kWh). RESULTS: Five activities were identified which were required to
develop one chest X-ray film. Human resource, capital, consumable and electricity
cost was MYR 1.48, MYR 1.98, MYR 2.15 and MYR 0.04, respectively. Total cost of
single chest X-ray was MYR 5.65 (USD 1.75). CONCLUSIONS: By applying ABC ap-
proach, we can havemore detailed and precise estimate of cost for specific activity
or service. Choice of repeating a chest X-ray for a patient can be based on our
findings, when cost is a limiting factor.
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OBJECTIVES: Refractory overactive bladder (OAB) with urge incontinence is an
underdiagnosed condition with substantial burden on the health care system and
patients with diminished quality-of-life. A significant number of patients will fail
conservative treatment with optimized medical-therapy (OMT) and may benefit
from minimally invasive procedures including sacral-neuromodulation (SNM) or
botulinum-toxin (BonT-A). The goal of this study was to estimate the cost-effec-
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tiveness of SNM versus OMT and BonT-A.METHODS:AMarkovmodel withMonte-
Carlo simulation was used to assess the ICER of SNM vs. BonT-A and OMT both in
deterministic (base-case) and probabilistic (sensitivity) analysis from a provincial
payer perspective over a 10-year time horizon with 9 month Markov-cycles. Clini-
cal data, healthcare resource utilization and utility scores were acquired from re-
cent publications and an expert panel of 7 surgeons. Cost data (2011 Dollars) were
derived from provincial health insurance policy, drug benefit formulary and hos-
pital data. All cost and outcomeswere discounted at 3% rate. RESULTS: The annual
(year 1-10) incremental QALY for SNM vs. BonT-A was 0.05-0.51 and SNM versus
OMTwas 0.19-1.76. The annual incremental cost of SNM versus BonT-Awas $7,237
in year-1 and -$9,402 in year-10 andwas between $8,878 to -$11,447 vs. OMT. In the
base-case deterministic analysis, the ICER for SNM vs. BonT-A and OMT were
within the acceptable range ($44,837 and $15,130 respectively) at 2nd-year of ther-
apy, and SNM was dominant in consequent years. In the base-case analysis the
probability of ICER being below the acceptability curve of (Willingness-To-
Pay$50,000) was 99% for SNM versus BonT-A at year 3 and 95% for OMT at
year-2. CONCLUSIONS: SNM is a cost-effective treatment option for the manage-
ment of patients with refractory OAB when compared to either BonT-A or OMT.
From a Canadian payers’ perspective, SNM should be considered as first-line treat-
ment option in management of patients with OAB.
PMD28
COST EFFECTIVENESS OF DRUG-ELUTING STENT FOR PATIENTS UNDERGOING
PERCUTANEOUS CORONARY REVASCULARIZATION IN HONG KONG
Yan B1, Lee V1, Liu M1, Reid C2, Yu CM1
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2Monash University, Melbourne, Vic,
Australia
OBJECTIVES: Drug-eluting stents (DES) reduce the need for target repeat revascu-
larization (TVR) compared with bare metal stents (BMS) but are two to three more
expensive. We aim to assess the cost-effectiveness of DES in Hong Kong.
METHODS: Consecutive patients undergoing percutaneous coronary intervention
(PCI) at our institution from September 2009 to September 2010 were evaluated.
Clinical outcomewasmeasured by the occurrence of major adverse cardiac events
(MACE), including death, myocardial infarction and clinically driven TVR. Direct
healthcare costs for index procedure, TVR, and follow-up costs were assessed. An
EQ-5D questionnaire was used to measure quality of life for the baseline and 6
months post PCI. Themain outcomewas the incremental cost-effective ratio (ICER)
for additional cost per TVR avoid and per quality-adjusted life-year (QALY) gained.
Costs are expressed inUS dollars (1USD 7.7HKD).RESULTS:A total of 761 patients
(DES476, BMS285) were evaluated. Clinically driven TVR occurred in 3.6% and
4.2%ofDES andBMSpatients, respectively (p0.68). One year total healthcare costs
was higher for DES patients (US$13,303) than BMS patients (US$12,075, p0.01).
Both groups experienced significant improvement in health utility score at 1 year
compared to baseline but therewas no significant difference betweenDES and BMS
patients (p0.07). QALY gained for DES and BMS patients were 0.415 and 0.375,
respectively (p0.61). The incremental cost per QALY gained was US$30,700 and
per TVR avoided was US$204,667. CONCLUSIONS: In this real-world PCI registry,
the use of DES was associated with significant improvement in quality of life and
low TVR rates which were similar in comparison with BMS. Based on these results,
DES can be considered cost-effective in terms of QALY gained but not for additional
TVR avoided in Hong Kong.
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OBJECTIVES: Early diagnosis of colorectal cancer (CRC) has been shown to improve
life expectancy, and colonoscopy and sigmoidoscopy are cost effective techniques
for CRC diagnosis in older age groups. The objective of this study was to determine
the cost-effectiveness (i.e., cost per QALY) of performing sigmoidoscopy, to check
for neoplasms in the distal colon, before performing colonoscopy in a group of
symptomatic 40-49 year old patients fromaUS societal perspective.METHODS: Los
Angeles County colonoscopy data was reviewed for symptomatic patients without
a family history of CRC to obtain neoplasm rates (N883). Records were collected
from April 2003 to April 2008. Additional parameters for the decision tree analysis
were extracted from a systematic literature review. RESULTS: Diagnostic sigmoid-
oscopy (DS) followed by diagnostic colonoscopy (DC) in patients with a distal ad-
vanced neoplasmwas shown to be themost cost-effective strategy (ICER$48,368),
DS followed by DC in patients with any distal neoplasmwas next (ICER$157,114),
and DC for all symptomatic patients was the least cost-effective (ICER$184,724).
DS followed by DC in patients with any distal neoplasm was sometimes less cost-
effective than DC for all symptomatic patients in a one-way sensitivity analysis. A
threshold analysis was completed for the cost of colonoscopy. CONCLUSIONS: DS
followed by DC in patients with distal advanced neoplasm was shown to be cost-
effective at a $50,000 willingness-to-pay threshold. The other diagnostic strategies
did not meet that threshold. Although, DS followed by DC in patients with any
distal neoplasms nearly met a threshold of $150,000. All strategies were most sen-
sitive to the stage of CRC at diagnosis and the prevalence of patientswith advanced
neoplasm. A colonoscopy cost reduction of over 40%was necessary tomake DC for
all symptomatic patients a cost-effective strategy at a $50,000 threshold and over
25% at a $100,000 threshold.
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OBJECTIVES:To evaluate cost-effectiveness of the implementation, in Colombia, of
different screening strategies for colorectal cancer (CRC): fecal occult blood stool
guaiac test (OB-GT), fecal occult blood immunochemical test (OB-IT), conventional
colonoscopy, sigmoidoscopy, OB-GT followed by sigmoidoscopy, and OB-IT test
plus sigmoidoscopy. METHODS: We designed a Markov model representing the
natural history of CRC in adult Colombians, for the whole lifespan of each individ-
ual, in one-year cycles, using local demographic and epidemiological data. This
model was then modified for each of the screening strategies, assuming detection
rates based on systematic review of the literature. Direct medical costs, from the
Colombian health system perspective (third-party payer), were estimated using
base-case data analysis from the Instituto Nacional de Cancerología (the Colom-
bian national cancer reference center) and applying two different national tariff
manuals (locally known as SOAT and ISS-2001). The costs assigned to each screen-
ing strategy included other diagnostic procedures included in standard protocols
as well as therapy for pre-neoplasic or cancer therapy at different stages of the
disease. A strategy was considered cost-effective if an incremental life year gained
(LYG) costs up to three times the per capita GDP of US$6225. Discount rate was 3%,
for costs and LYG. RESULTS: The cost in US$ per LYG differedmarkedly depending
on the tariff manual used. In both cases, however, biennial OB-GT was cost-effec-
tive (US$10,641 and US$2,694 per LYG), compared with annual OB-GT (US$ 18,902
and US$27,237 per LYG), and biennial OB-IT (US$46.439 and US$14.040 per LYG).
Other screening strategies were clearly not cost-effective under our assumptions.
Probabilistic sensitivity analysis did not change results significantly.
CONCLUSIONS: The most cost-effective screening strategy for CRC in Colombia
(and the only one below our threshold) was biennial feccal occult blood guaiac test.
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OBJECTIVES: Gefitinib, selective epidermal growth factor receptor tyrosine kinase
inhibitor improves progression free survival and overall survival for non-small-cell
lung cancer (NSCLC) patients. However patients with EGFR gene wild-type don’t
benefit from gefitinib. METHODS: We performed cost-effectiveness analysis of
EGFR testing and gefitinib treatment as first-line therapy for NSCLC patients. In our
analysis, we considered three groups:(A) gefitinib treatment for all the patients
without EGFR testing, (B) chemotherapy (carboplatin / paclitaxel) for all the pa-
tients without EGFR testing, and (C) gefitinib treatment for mutation patients and
chemotherapy(carboplatin / paclitaxel) for wild-type patients with EGFR testing.
The cost-effectiveness of two comparison groups was calculated: group A vs. C
(cost-effectiveness of EGFR testing) and and group B versus C (cost-effectiveness of
gefitinib treatment with EGFR testing). Outcome of gefitinib or chemotherapy was
based on Iressa Pan-Asia Study (IPASS) [FukuokaM et al. (2011)]. Onlymedical costs
were included from the perspective of Japanese healthcare payer (the cost of EGFR
testing is JPY 20,000 (USD 260, 1USDJPY77). Discount wasn’t performed because
of short time horizon. RESULTS: ICER of gefitinib with EGFR testing was JPY 900,000
(USD 12,000) (groupA vs. C) per life year gained (LYG) and the ICER of chemotherapy
with EGFR testing was JPY 3,580,000 (USD 46,500) (group B vs. C) per LYG. The cost
of EGFR testing was not influenced on the results. If the cost of EGFR testing is
increased to JPY 80,000 (USD 1,000), the ICER was changed to JPY 1,100,000 (USD
14,000) (group A vs. C) per LYG and JPY 4,870,000 (USD 63,000) per LYG, respectively.
CONCLUSIONS: EGFR testing is cost-effective, however it is not clearly shown that
gefitinb is cost-effective even if EGFR testing is used. EGFR testing is also recom-
mended from the economic perspective if gefitinib is considered to be adminis-
tered.
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OBJECTIVES:Weaim to evaluate the cost-effectiveness of drug-eluting stents (DES)
in a real world setting of multi-vessel percutaneous coronary intervention (PCI).
METHODS: We analyzed 795 consecutive patients undergoing PCI at our institu-
tion. Health outcomeswas estimated in terms of quality adjusted life years (QALYs)
gained measured using EQ-5D at baseline, 6 and 12 months after PCI. Total direct
healthcare costs including cost of index procedure and follow-up costs incurred
over 12 months were calculated. Incremental cost-effective ratio (ICER) per QALY
gained was used to evaluate the cost-utility of DES. RESULTS: Of the 795 patients,
482, 201 and 61 patients underwent single-, 2- and 3-vessel PCI, respectively. DES
was used in 62.7%, 62.6%, 58.7% and 68.9% in overall, single-, 2- and 3-vessel PCI
procedures, respectively. There was progressive increase in QALY gain for patients
who had PCI to 3- (0.43) than in 2- (0.40) and 1-vessel (0.39, p0.01). DES was
associated with higher 1 year total healthcare cost in all 3 groups but was more
effective only in patientswhounderwent 2- and 3-vessel PCIwith an ICER perQALY
gained of US$3,131 and US$21,290, respectively. CONCLUSIONS: In this real-world
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